Benitec Biopharma
BNTC
56 hedge funds and large institutions have $325M invested in Benitec Biopharma in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 27 increasing their positions, 10 reducing their positions, and 7 closing their positions.
170% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 10
22% more capital invested
Capital invested by funds: $265M → $325M (+$59.4M)
1.79% more ownership
Funds ownership: 86.42% → 88.21% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less funds holding
Funds holding: 57 → 56 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.89M |
| 2 |
Goldman Sachs
New York
|
+$2.21M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.05M |
| 4 |
State Street
Boston,
Massachusetts
|
+$732K |
| 5 |
AIC
AWM Investment Company
New York
|
+$574K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$1.43M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$503K |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$442K |
| 4 |
Morgan Stanley
New York
|
-$232K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$207K |
BNTC Hedge Fund Activity: Q3 2025 in Review
56 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q3 2025, worth a combined $325M — up 22% from $265M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BNTC and 6 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 27 added.
The largest buyer was BlackRock, adding an estimated $2.89M. The largest seller was Franklin Resources, cutting an estimated $1.43M.
- 56 institutional investors held Benitec Biopharma (BNTC) as of Q3 2025, down from 57 in Q2 2025.
- Funds reported $325M of Benitec Biopharma stock for Q3 2025, up 22% quarter-over-quarter.
- 6 funds opened new Benitec Biopharma positions in Q3 2025 and 7 closed out, a net change of -1 holder.
- The largest Benitec Biopharma buyer in Q3 2025 was BlackRock, an estimated $2.89M added.
- The largest Benitec Biopharma seller in Q3 2025 was Franklin Resources, an estimated $1.43M sold.
Based on aggregated 13F filings for Q3 2025.